#MXCT

StockTitan

@stocktitan.net

2 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results MaxCyte (Nasdaq: MXCT) provided preliminary unaudited results for the quarter and year ended December 31, 2025. Q4 core revenue is expected to be $6.6M–$6.7M and FY2025 core revenue is expected to be $29.5M–$29.6M. SPL program revenue is expected to be $0.4M–$0.6M for Q4 and $3.3M–$3.5M for FY2025. Cash, cash equivalents, and investments are expected to be approximately $155.6M as of December 31, 2025. Management described 2025 as challenging but said core revenue was in line with guidance, noted cost-structure improvements and program rationalization, and stated an expectation to return to revenue growth in H2 2026. Final audited results are expected in March 2026.

#MXCT MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/MXCT/max-cyte-annou...

StockTitan

@stocktitan.net

4 months ago

MaxCyte Announces Planned CFO Transition in 2026 MaxCyte (Nasdaq: MXCT) announced that Chief Financial Officer Douglas Swirsky will transition from his CFO role in the first half of 2026. Mr. Swirsky will remain CFO until a successor is appointed, will support a structured successor search, and will continue in an advisory capacity after the transition to support strategic initiatives and continuity.The company and Mr. Swirsky say the planned, orderly handoff is not expected to affect operations, results, financial reporting cadence, or strategic priorities.

#MXCT MaxCyte Announces Planned CFO Transition in 2026

www.stocktitan.net/news/MXCT/max-cyte-annou...

StockTitan

@stocktitan.net

4 months ago

#MXCT MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

www.stocktitan.net/news/MXCT/max-cyte-repor...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Small-cap stocks in new ADX downtrend, Thu Nov 6th - #FTFT #GYRE #HTLD #DMLP #CVAC #INGN #JSPR #BHST #KPRX #MXCT #AIOT #WDH #SITC #NPB #NOTE #MED #JBI #DEA #CNMD #BLND #SGN #KAPA #UAVS #VVPR #TRNS #RPD #PSEC - More: crystalequityresearch.com/trade-alerts... - #smallcap

StockTitan

@stocktitan.net

4 months ago

#MXCT MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

www.stocktitan.net/news/MXCT/max-cyte-repor...

StockTitan

@stocktitan.net

5 months ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MaxCyte (Nasdaq: MXCT) signed a Strategic Platform License (SPL) with Moonlight Bio on Oct 6, 2025 to support development and scalable manufacturing of Moonlight's engineered T cell therapies for solid tumors. Moonlight gains non-exclusive research, clinical, and commercial rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform. MaxCyte will receive annual licensing fees and program-related revenue while Moonlight will use GMP-ready electroporation and regulatory support to build clinical manufacturing processes.

#MXCT MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

www.stocktitan.net/news/MXCT/max-cyte-annou...

StockTitan

@stocktitan.net

5 months ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability MaxCyte (NASDAQ:MXCT), a cell-engineering platform technology company, has announced a significant operational restructuring to optimize costs and accelerate profitability. The plan includes a 34% reduction in global workforce, expected to generate $13.6 million in annual savings.The company reiterated its 2025 guidance, expecting core revenue to be flat to down 10% compared to 2024, with $5 million in SPL program-related revenue. MaxCyte projects to maintain at least $155 million in cash, cash equivalents, and investments by year-end.

#MXCT MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

www.stocktitan.net/news/MXCT/max-cyte-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Small-cap stocks with strong volume declines, Thu Aug 7th - #ULBI #TEAD #SANA #ROOT #PEPG #OCCI #MXCT #HNST #GENK #FWRG #ESTA #CLFD #BTMD #ATRO #UTI #TPVG #SMA #MLR #IIPR #BOW - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

7 months ago

MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation MaxCyte grants Adicet Bio rights to its Flow Electroporation platform for gamma delta T cell therapy development. Partnership enables next-gen cancer treatments. Learn more.

#MXCT MaxCyte Signs Platform License Agreement with Adicet Bio

www.stocktitan.net/news/MXCT/max-cyte-signs...

StockTitan

@stocktitan.net

10 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MaxCyte (NASDAQ: MXCT) reported its Q1 2025 financial results, showing mixed performance. Total revenue decreased 8% to $10.4 million compared to Q1 2024. Core business revenue grew marginally by 1% to $8.2 million, while Strategic Platform License (SPL) Program-related revenue declined 32% to $2.1 million. The company added TG Therapeutics as a new SPL client, bringing total active SPLs to 29. MaxCyte maintained a strong financial position with $174.7 million in cash and investments. The company reiterated its 2025 guidance, expecting core revenue growth of 8-15% and SPL Program-related revenue of approximately $5 million. Gross margin slightly decreased to 86% from 88% in Q1 2024, while net loss increased to $10.3 million compared to $9.5 million in the same period last year.

#MXCT MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

www.stocktitan.net/news/MXCT/max-cyte-repor...

StockTitan

@stocktitan.net

1 year ago

MaxCyte Core Business Surges 20% as Company Projects Strong 2025 Growth MaxCyte's core revenue jumps 20% in Q4, maintains $190M cash position, and projects 8-15% growth for 2025. Strategic platform licenses expand to 28 partnerships.

#MXCT MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

www.stocktitan.net/news/MXCT/max-cyte-repor...

marketshareai.uk

@marketshareai.bsky.social

1 year ago

🧬 MaxCyte licenses cell engineering platform to TG Therapeutics for autoimmune disease therapy. Bolsters pipeline with promising allogeneic CAR T approach. $MXCT #Healthcare

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/mxct/7610W

#MXCT #AIM #FTSE

StockTitan

@stocktitan.net

1 year ago

Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment MaxCyte partners with TG Therapeutics, licensing its Flow Electroporation® platform for breakthrough MS cell therapy development, securing recurring revenue stream.

#MXCT MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

www.stocktitan.net/news/MXCT/max-cyte-signs...

marketshareai.uk

@marketshareai.bsky.social

1 year ago

🏥 MaxCyte expands cell therapy capabilities, acquires gene editing safety analytics leader SeQure Dx. Advancing solutions for cell and gene therapy developers.

Get ahead with today's top stories 👇

https://marketshareai.uk/news/lse/mxct/1990V

#MXCT #AIM #FTSE

StockTitan

@stocktitan.net

1 year ago

MaxCyte's Strategic Move: $7M Deal Transforms Gene Therapy Safety Testing Landscape MaxCyte strengthens its cell & gene therapy portfolio by acquiring SeQure Dx for $4.5M, expanding into important safety testing services with potential earnout of $2.5M based on performance.

#MXCT MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

www.stocktitan.net/news/MXCT/max-cyte-acqui...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #MXCT ) MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

StockTitan

@stocktitan.net

1 year ago

MaxCyte Q4 Revenue Grows 16%, Adds Six Strategic Partners Amid Cell Therapy Milestone MaxCyte reports Q4 core revenue of $8.3-8.5M, up 16% YoY, with $190M cash position. Company expands partnerships and supports first non-viral gene edited cell therapy approval.

#MXCT MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/MXCT/max-cyte-annou...

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #MXCT ) MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% MaxCyte streamlines operations with strategic workforce reduction, projects $5.8M in savings for 2025 while raising revenue guidance. Company maintains strong $185M cash position.

#MXCT MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

#stocks #news #StockMarket

www.stocktitan.net/news/MXCT/max-cyte-annou...

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #MXCT ) MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

#StockMarket #News